Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2022 | Highlights in myeloma from BSH

Guy Pratt • 4 Apr 2022
BSH 2022
Multiple Myeloma Antibodies Iberdomide Teclistamab
CARTITUDE-2 FITNESS MajesTEC-1 Myeloma XV RADAR

Guy Pratt, MD, FRCP, FRCPath, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, shares his highlights from this year’s BSH meeting. Prof. Pratt first comments on the new BSH guidelines for the treatment of multiple myeloma, as well as updates on ongoing UK clinical trials in myeloma. Moving forward, Prof. Pratt mentions presentations on amyloidosis, COVID-19 vaccination in patients with hematological malignancies, and promising data on teclistamab and iberdomide. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.

More from Guy Pratt

1:44
Optimal treatment sequencing in multiple myeloma
Guy Pratt • 4 Apr 2022
1:16
Latest advances in immunotherapy for multiple myeloma: targets, alloCAR-Ts & immunomodulatory drugs
Guy Pratt • 4 Apr 2022
2:17
Cilta-cel: a paradigm shift in the treatment of multiple myeloma
Guy Pratt • 4 Apr 2022
1:48
The evolving treatment landscape in multiple myeloma & ongoing research
Guy Pratt • 4 Apr 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals